美卡舍明-林菲培（Mecasermin Rinfabate）与美卡舍明（Increlex）有所不同，本药为重组人胰岛素样生长因子-1（rh-IGF-1）与重组人胰岛素样生长因子结合蛋白-3（rh-IGFBP-3）组成的一种二元蛋白复...
基于6个网页-相关网页
But Tercica has orphan status for its drug, which should protect Increlex from competition for seven years.
FORBES
Insmed, another biotech that is developing a similar drug, had filed a petition with the FDA regarding Increlex's safety profile.
The Food and Drug Administration has approved Increlex, a medicine developed by biotech Tercica to treat a hormone deficiency that causes short stature and other health problems for 6, 000 children.
应用推荐
模块上移
模块下移
不移动